Investment Rating - The report maintains a "BUY" rating for CSPC Pharmaceutical, indicating a potential return of over 15% over the next 12 months [15]. Core Insights - CSPC's total revenue is projected to decline by 7.8% YoY to RMB29.0 billion in FY24, primarily due to significant drops in oncology and cardiovascular drug sales [7]. - The company anticipates a return to positive organic revenue growth in FY2025, driven by new product launches and business development (BD) initiatives [7]. - CSPC has made substantial progress in out-licensing innovative assets, aiming to secure 3-4 out-licensing deals annually to generate recurring revenue [7]. - The target price for CSPC is revised to HK$5.71 from HK$5.97, reflecting a 15.5% upside from the current price of HK$4.94 [3][7]. Financial Summary - Revenue for FY23 is reported at RMB31,450 million, with a slight YoY growth of 1.7%, while FY24 revenue is expected to drop to RMB29,009 million [2][12]. - Net profit for FY23 is RMB6,072.7 million, showing a decline of 2.6% YoY, with further expected declines in FY24 to RMB4,338.8 million [2][12]. - The earnings per share (EPS) for FY23 is reported at RMB0.49, with projections of RMB0.37 for FY24 [2][12]. Business Development and Pipeline - CSPC's business development efforts are expected to create a sustainable revenue stream, with a robust pipeline of 40-50 assets identified for out-licensing potential [7]. - The company is focusing on clinical trials for its EGFR ADC (SYS6010), which is currently in Phase 3 development globally [7]. Market Performance - CSPC's market capitalization is reported at HK$58,871 million, with a 52-week high of HK$7.12 and a low of HK$4.34 [3]. - The stock has shown a 1-month absolute performance of 4.9% and a 3-month performance of 3.3% [5].

Investment Rating - The investment rating for the company is "Recommended" [1] Core Views - The company is expected to improve sales while actively optimizing its land reserve structure. Despite a decline in net profit, revenue is projected to grow, indicating a focus on operational efficiency and market positioning [4][7]. Summary by Relevant Sections Financial Performance - In 2024, the company achieved revenue of 86.4 billion yuan, a year-on-year increase of 7.7%. However, the net profit attributable to shareholders was 1.04 billion yuan, reflecting a significant decline of 67.3% [4]. - The gross profit margin decreased by 4.8 percentage points to 10.5% in 2024, impacting overall profitability [7]. Sales and Market Strategy - The company aims for a sales target of 120.5 billion yuan in 2025, representing a growth of 5.2%. The contract sales for the first two months of 2025 reached 12.83 billion yuan, up 23.8% year-on-year [7]. - The company has a marketable inventory valued at approximately 235.4 billion yuan, with a focus on first-tier and key second-tier cities for land acquisitions [7]. Financial Health - The company completed equity investments of 29.46 billion yuan in 2024, with 82.7% of the new land reserves located in major cities like Beijing, Shanghai, and Guangzhou [7]. - The company maintains a healthy financial status, with a debt-to-asset ratio of 74.6% and an average borrowing cost of 3.49% [1][7]. Future Projections - Revenue is expected to continue growing, with projections of 94.2 billion yuan in 2025 and 102.2 billion yuan in 2026, reflecting a compound annual growth rate of approximately 8% [6][10]. - The earnings per share (EPS) forecast for 2025 is adjusted to 0.27 yuan, with a price-to-earnings (P/E) ratio of 18.0 times [7][10].

Investment Rating - The investment rating for the company is "Buy" with a target price of 8.15 HKD [8][9]. Core Views - The company achieved a revenue of 1.346 billion RMB in 2024, representing a 23% year-over-year increase, and a net profit of 274 million RMB, which is a 50% year-over-year increase, aligning with previous profit forecasts [1]. - The growth in profit is attributed to the execution of joint replacement contracts, with a 25.8% year-over-year increase in joint business revenue, and continuous optimization of sales, management, and R&D expense ratios [1]. - For 2025, the company is expected to enter a new cycle of simultaneous volume and price increases, with a projected net profit growth rate of 23% [1]. Summary by Sections Joint Business Segment - The joint segment generated revenue of 1.134 billion RMB in 2024, up 25.8% year-over-year, primarily due to successful contract renewals and price increases for certain products [2]. - The impact of contract renewals is expected to be more pronounced in 2025, with price increases exceeding 15% for full ceramic and knee joints, and a recovery in surgical volumes anticipated [2]. Spine and Trauma Segment - The spine and trauma segment achieved revenue of 127 million RMB in 2024, a 3% year-over-year increase, with expectations for steady growth in 2025 driven by the gradual increase in volume during the contract renewal period [3]. Customization Platform - The customization platform generated revenue of 51 million RMB in 2024, a 3.5% year-over-year increase, with expectations for stable growth in 2025 due to advancements in smart devices and ongoing overseas market expansion [4]. Profit Forecast and Valuation - The company is projected to have EPS of 0.30 RMB in 2025, with a target price set at 8.15 HKD based on a 25x PE ratio for 2025 [5]. - The expected revenues for 2025 are 1.639 billion RMB, with a net profit of 338 million RMB, reflecting a 23.3% increase from 2024 [7].

Investment Rating - The investment rating for the company is "Buy" with a target price of 6.88 HKD [8][9]. Core Views - The company is expected to achieve a revenue of 615 million RMB in 2024, representing a year-on-year growth of 39.5%, with a significant reduction in net loss to 228 million RMB [1]. - The TAVR segment is projected to see a revenue increase of 40% year-on-year in 2024, driven by an increase in market share and product iterations [2]. - The neurointervention segment is also expected to grow by 39% year-on-year in 2024, benefiting from new product launches and import substitution opportunities [3]. - Long-term growth is anticipated from the TAVR pipeline, with new products expected to launch from late 2025 [4]. - The company is projected to achieve revenues of 818 million RMB, 1.066 billion RMB, and 1.540 billion RMB in 2025, 2026, and 2027 respectively, with a net loss of 83 million RMB in 2025 turning to a profit of 10 million RMB in 2026 [5][20]. Summary by Sections TAVR Segment - The TAVR segment is expected to generate 260 million RMB in revenue in 2024, with a 40% year-on-year growth, and a market share increase to 25% [2]. - The company plans to expand its market presence by increasing hospital partnerships and launching new products [2]. Neurointervention Segment - The neurointervention segment is projected to achieve 356 million RMB in revenue in 2024, with a 39% year-on-year growth, driven by new product launches and import substitution [3]. - The segment is expected to benefit from regional procurement policies and the introduction of new products [3]. TMV/TTV Pipeline - The TMV/TTV pipeline is progressing well, with potential sales exceeding 2 billion RMB by 2033, supported by ongoing clinical trials and product registrations [4]. Profit Forecast and Valuation - The company is expected to achieve revenues of 818 million RMB in 2025, with a net loss of 83 million RMB, improving to a profit of 10 million RMB in 2026 [5][20]. - A DCF valuation method estimates the target price at 6.88 HKD, reflecting the long-term growth potential of the company's pipeline [5][13].

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company is expected to achieve a revenue of 10.322 billion RMB in 2024, representing a year-on-year growth of 3.67%, and an adjusted EBITDA of 4.876 billion RMB, reflecting a growth of 10.76% in 2025 [5][3] - The growth in AI inference demand is anticipated to reduce the domestic data center vacancy rate, leading to valuation enhancement and performance improvement opportunities for the company [1][4] - The company has signed new domestic orders amounting to 152MW, indicating a positive trend in domestic business [2] Summary by Sections Financial Performance - In 2024, the company is projected to achieve an operating income of 10.322 billion RMB, a 5.5% increase from the previous year, and an adjusted EBITDA of 4.876 billion RMB, a 3% increase [1] - For 2025, the total revenue is expected to be between 11.29 billion RMB and 11.59 billion RMB, with an adjusted EBITDA forecasted between 5.19 billion RMB and 5.39 billion RMB [3] Business Development - As of the end of Q4 2024, the company’s operational area reached 613,583 square meters, with a cabinet utilization rate of 73.8% [2] - The company plans to increase its capital expenditure budget to 4.3 billion RMB in 2025 to meet the construction needs of the new signed orders [3] Valuation - The report employs a Sum-of-the-Parts (SOTP) valuation method, assigning a target EV/EBITDA multiple of 15x for domestic operations, leading to a target price of 36.37 HKD per share [4][10]

Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of the stock [1][8]. Core Insights - The company has shown steady expansion in its store network and the effectiveness of its explosive product strategy is becoming evident [1][7]. - In 2024, the company achieved a revenue of 6.47 billion yuan, reflecting a year-on-year increase of 6%, while the net profit attributable to shareholders was 231 million yuan, a decrease of 4% [5][8]. - The company plans to continue focusing on explosive product combinations and enhancing its supply chain efficiency to improve profitability [6][7]. Summary by Sections Basic Data - Current stock price is HKD 2.01, with a total market capitalization of HKD 55.2 billion and total shares outstanding of 2,747.4 million [2]. Financial Performance - In the second half of 2024, the company reported revenue of 3.80 billion yuan, a 14% increase year-on-year, and a net profit of 145 million yuan, a 10% increase [5][8]. - The gross profit margin for 2024 decreased by 0.3 percentage points to 21.90%, primarily due to the increased volume of low-margin products [6]. Market Strategy - As of the end of 2024, the company had 10,150 stores, with a net increase of 287 stores in rural areas [7]. - The pre-paid card amount increased by 37% in 2024, indicating a successful membership strategy [7]. Profit Forecast - The company expects earnings per share (EPS) of 0.09, 0.10, and 0.12 yuan for 2025, 2026, and 2027 respectively, with corresponding price-to-earnings (PE) ratios of 20, 18, and 16 [8][11].

Investment Rating - The report assigns a "Buy" investment rating for the company, marking the first coverage of the stock [1][8]. Core Views - The company has shown steady expansion in its store network and the effectiveness of its explosive product strategy is becoming evident [1][7]. - In 2024, the company achieved a revenue of 6.47 billion yuan, a year-on-year increase of 6%, while the net profit attributable to the parent company was 231 million yuan, a decrease of 4% [5][8]. - The company plans to continue focusing on explosive product combinations and enhancing its supply chain efficiency to improve profitability [6][7]. Summary by Sections Basic Data - Current stock price is HKD 2.01 with a total market capitalization of HKD 55.2 billion and total shares outstanding of 2,747.4 million [2]. Financial Performance - In 2024, the company reported a revenue of 6.47 billion yuan and a net profit of 231 million yuan, with a dividend payout ratio of 89% [5][8]. - The gross margin decreased by 0.3 percentage points to 21.9% due to the increased volume of low-margin products [6]. Investment Highlights - The company is enhancing its supply chain efficiency and increasing investment in brand promotion, leading to a rise in sales expenses by 1 percentage point to 10.27% [6]. - The number of stores reached 10,150 by the end of 2024, with a net increase of 287 stores in rural areas [7]. - The prepayment card amount increased by 37%, indicating a growing membership base and improved customer retention [7]. Earnings Forecast - The company is expected to see earnings per share (EPS) of 0.09, 0.10, and 0.12 yuan for 2025, 2026, and 2027 respectively, with corresponding price-to-earnings (PE) ratios of 20, 18, and 16 times [8][11].

Investment Rating - The report maintains a "Buy" recommendation for Yuexiu Property (0123.HK) [1] Core Views - The company is expected to improve sales while actively optimizing its land reserve structure [1][7] - In 2024, the company achieved revenue of 86.4 billion yuan, a year-on-year increase of 7.7%, but the net profit attributable to shareholders decreased by 67.3% to 1.04 billion yuan [4][6] - The company aims for a sales target of 120.5 billion yuan in 2025, representing a year-on-year growth of 5.2% [7] Financial Performance - Revenue and profit projections for the upcoming years are as follows: - 2024: Revenue of 86.4 billion yuan, net profit of 1.04 billion yuan - 2025: Revenue of 94.2 billion yuan, net profit of 1.09 billion yuan - 2026: Revenue of 102.2 billion yuan, net profit of 1.14 billion yuan - 2027: Revenue of 110.4 billion yuan, net profit of 1.18 billion yuan [6][9] - The gross margin is projected to decline to 10.5% in 2024, down from 15.3% in 2023 [6][10] Land Acquisition and Financial Strategy - In 2024, the company completed equity investments of 29.46 billion yuan, with 100% of new land reserves located in first-tier and key second-tier cities [7] - The company maintains a healthy financial status, with a debt-to-asset ratio of 74.6% and an average borrowing cost of 3.49% [1][7] Market Position and Outlook - As a local state-owned enterprise in the Greater Bay Area, the company is positioned to expand its market share during the industry downturn, leveraging its financing advantages and diversified land acquisition strategies [7] - The report suggests that despite the ongoing industry adjustments, the company has the potential for growth due to its financial strengths and land reserve optimization [7][8]

上 市 公 司 房地产 2025 年 03 月 31 日 保利物业 (06049) | 市场数据： | 2025 年 03 月 31 日 | | --- | --- | | 收盘价（港币） | 31.30 | | 恒生中国企业指数 | 8516.55 | | 52 周最高/最低（港币） | 40.65/24.25 | | H 股市值（亿港币） | 173.19 | | 流通 H 股（百万股） | 153.33 | | 汇率（人民币/港币） | 1.0836 | 一年内股价与基准指数对比走势： 94% -6% 44% 04/02 05/02 06/02 07/02 08/02 09/02 10/02 11/02 12/02 01/02 02/02 03/02 HSCEI 保利物业 资料来源：Bloomberg 证券分析师 袁豪 A0230520120001 yuanhao@swsresearch.com 曹曼 A0230520120003 caoman@swsresearch.com ——业绩稳定增长，管理费用改善 报告原因：有业绩公布需要点评 买入（维持） 联系人 曹曼 (8621)23297818× cao ...

2025 年 3 月 31 日 | 总股本(亿股) | 90.67 | | --- | --- | | 总市值(亿港元)： | 532.25 | | 一年最低/最高(港元)： | 3.26/7.38 | | 近 3 月换手率(%)： | 21.16 | 公司研究 政府补助减少拖累 24H2 利润，开始实施全龄营养战略 ——中国飞鹤（6186.HK）2024 年年度业绩点评 买入（维持） 当前价：5.87 港元 作者 分析师：陈彦彤 执业证书编号：S0930518070002 021-52523689 chenyt@ebscn.com 分析师：汪航宇 执业证书编号：S0930523070002 021-52523174 wanghangyu@ebscn.com 分析师：聂博雅 执业证书编号：S0930522030003 021-52523808 nieboya@ebscn.com | 市场数据 | | --- | 股价相对走势 -20% 0% 20% 40% 60% 80% 100% 24/04 24/05 24/06 24/07 24/08 24/09 24/10 24/11 24/12 25/01 25/0 ...